Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings

D Weycker, R Barron, A Kartashov… - Journal of Oncology …, 2014 - journals.sagepub.com
D Weycker, R Barron, A Kartashov, J Legg, GH Lyman
Journal of Oncology Pharmacy Practice, 2014journals.sagepub.com
Objective To examine the incidence, treatment, and consequences of febrile neutropenia
across inpatient and outpatient care settings. Methods Data were obtained from Humedica's
National Electronic Health Record-Derived Longitudinal Patient-Level Database (2007–
2010). The study population included adult patients who received myelosuppressive
chemotherapy for a solid tumor or non-Hodgkin's lymphoma. For each patient, each
chemotherapy regimen course and each cycle within each regimen course was …
Objective
To examine the incidence, treatment, and consequences of febrile neutropenia across inpatient and outpatient care settings.
Methods
Data were obtained from Humedica's National Electronic Health Record-Derived Longitudinal Patient-Level Database (2007–2010). The study population included adult patients who received myelosuppressive chemotherapy for a solid tumor or non-Hodgkin’s lymphoma. For each patient, each chemotherapy regimen course and each cycle within each regimen course was characterized. Febrile neutropenia episodes were identified on a cycle-specific basis based on any of the following: (1) absolute neutrophil count <1.0 × 109/L and evidence of infection or fever; (2) inpatient diagnosis of neutropenia, fever, or infection; (3) outpatient diagnosis of neutropenia and non-prophylactic antimicrobial use; or (4) mention of febrile neutropenia in physician notes. Febrile neutropenia episodes were categorized as inpatient or outpatient based on the initial setting of care (i.e. acute-care inpatient facility vs. ambulatory care facility). Febrile neutropenia consequences included hospital length of stay and mortality (inpatient cases only), as well as number of febrile neutropenia-related outpatient encounters.
Results
Among the 2131 patients in this study, 401 experienced a total of 458 febrile neutropenia episodes. Risk of febrile neutropenia during the chemotherapy regimen course was 16.8% (95% CI: 15.3, 18.4). In cycle 1 alone, risk of febrile neutropenia was 8.1% (7.1, 9.3). Most febrile neutropenia episodes (83.2%) were initially treated in the inpatient setting; the hospital mortality rate was 8.1% (5.8, 11.1), and mean hospital length of stay was 8.4 days (7.7, 9.1). Among febrile neutropenia episodes initially treated in the outpatient setting (16.8%), the mean number of outpatient management encounters was 2.6 (2.1, 3.1), most of which were in the physician’s office (69.2%) or emergency department (26.9%).
Conclusions
Febrile neutropenia remains a common occurrence among patients receiving myelosuppressive chemotherapy and typically results in extended hospitalization and, for many patients, death. A minority of patients are, however, treated exclusively on an outpatient basis.
Sage Journals
以上显示的是最相近的搜索结果。 查看全部搜索结果